Company intelligence / Profile preview

ImaginAb

Inglewood, California, United Statesimaginab.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Lead imaging candidate CD8 ImmunoPET is in Phase 2 clinical trials. Also developing a pivotal prostate cancer imaging agent in Phase 2 clinical trials.[3]

Therapeutic areas: Oncology
Modalities: Minibody antibodiesradiopharmaceuticalsimaging agents
Industry: Medical Imaging

Drug pipeline

1 asset

zirconium zr-89 crefmirlimab berdoxam

Phase 2

Indications: Melanoma, Merkel Cell Carcinoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer

Partnerships

DuChemBio Co, Ltd. (manufacturing and distribution partnership)[5]numerous pharmaceutical and biotech companies (for use of CD8 ImmunoPET in clinical trials)[3]

Beyond the preview

Go deeper on ImaginAb.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ImaginAb.

Explore the full profile